Polymeric nanoparticles for enhancing antiretroviral drug therapy

Drug Delivery

Volumn 15, Issue 8, 2008, Pages 493-501

  Govender, T ^a   Ojewole, E ^a   Naidoo, P ^a   Mackraj, I ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

Author keywords

AIDS; Antiretroviral; HIV; Nanoparticles; Novel drug delivery

Indexed keywords

ANTIRETROVIRUS AGENT; CGP 57813; CGP 70726; CHOLESTERYL HYDROGEN SUCCINATE; DELAVIRDINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; EUDRAGIT; HEXYL CYANOACRYLATE; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; MACROGOL; METHACRYLIC ACID METHYL ESTER; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; POLY(ISOHEXYL CYANOACRYLATE); POLYBUTYL CYANOACRYLATE; POLYMER; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SOLID LIPID NANOPARTICLE; STAVUDINE; SULFOPROPYL METHACRYLATE; TAUROCHOLIC ACID; TRIPALMITIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD BRAIN BARRIER; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NANOTECHNOLOGY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SURFACE CHARGE; TARGET CELL;

ANTI-HIV AGENTS; DRUG CARRIERS; HIV INFECTIONS; HIV-1; HUMANS; NANOPARTICLES; PARTICLE SIZE;

EID: 54049086948     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717540802321776     Document Type: Review

References (56)

1. Amiji, M. M., Vyas, T. K., and Shah, L. K. 2006. Role of nanotechnology in HIV/AIDS treatment: potential to overcome the viral reservoir challenge. Discov. Med. 6 (34):157-162.
2. Bender, A., Schfer V., Steffan A. M., Royer C., Kreuter J., Rubsamen-Waigmann H., and von Briesen H. 1994. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145(34):215-220.
3. Bender, A. R., von Briesen, H., Kreuter, J., Duncan, I. B., and Rubsamen-Waigimann H. 1996. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/ macrophages in vitro. Antimicrob. Agents Chemother. 40(6):1467-1471.
4. Benghuzzi, H. 2006. Long-term sustained delivery of 3′-azido- 2′3′-dideoxythymidine in vivo by means of HA and TCP delivery devices. Biomed. Sci. Instrum. 36:343-348.
5. Boudad, H., Legrand, P., Appel, M., Coconnier, M. H., and Ponchel G. 2001. Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavir. STP Pharma. Sci. 11(5):369-375.
6. Brannon-Peppas, L., and Blanchette, J. O. 2004. Nanoparticle and targeted systems for cancer therapy. Adv. Drug. Deliv. Rev. 56(11):1649-1659.
7. Cohen, O. J., Kinter, A., and Fauci, A. S.. 1997. Host factors in the pathogenesis of HIV disease. Immunol. Rev. 159:31-48.
8. De Jaeghere, F., Allemann, E., Kubel, F., Galli, B., Cozens, R., Doelker, E., and Gurny, R.. 2000. Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state. J. Control Release 68(2):291-298.
9. Dembri, A., Montisci, M. J., Gantier, J. C., Chacun, H., and Ponchel, G. 2001. Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissues. Pharm. Res. 18(4):467-473.
10. Dipali, S. R., Lin, Y. J., Ravis, G. V., and Betageri, G. V. 1997. Pharmacokinetics and tissue distribution of a long circulating liposomal formulation of 2′3′ dideoxyinosine. Int. J. Pharmaceutics 152(1):89-97.
11. Dou, H., Destache, C. J., Morehead, J. R., Mosley, R. L., Boska, M. D., Kingsley, J., Gorantla, S., Poluektova, L., Nelson, J. A., Chaubal, M., Werling, J., Kipp, J., Rabinow, B. E., and Gendelman, H. E. 2006. Development of macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 108(8):2827-2837.
12. Dou, H., Morehead, J., Destache, C. J., Kingsley, J. D., Shlyakhtenko, L., Zhou, Y., Chaubal, M., Werling, J., Kipp, J., Rabinow, B. E., and Gendelman, H. E. 2007. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 358(1):148-158.
13. Dutta, T., Agashe, H. B., Garg, M., Balasubramanium, P., Kabra, M., and Jain, N. K. 2007. Poly (propyleneimine) dendrimer-based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target 15(1):89-98.
14. Fauci, A. S., and Lane, H. C. 1991. The acquired immunodeficiency syndrome (AIDS): in Harrison's Principles of Internal Medicine. New York: McGraw-Hi Publishing. 1402-1410.
15. Gagne, J. F., Desormeaux, A., Perron, S., Tremblay, M. J., and Bergeron, M. G. 2002. Targeted delivery of indinavir to HIV-1 primary reservoirs with immunoliposomes. Biochim. Biophys. Acta. 1558(2):198-210.
16. Girard, M. P., Osmanov, S. K., and Kieny, M. P. 2006. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24(19):4062-4081.
17. Gopinath, D., Ravi, D., Rao, B. R., Apte, S. S., Renuka, D., and Rambhau, D. 2004. Ascorbyl palmitate vesicles (Aspasomes): formation, characterization and applications. Int. J. Pharm. 271(1-2):95-113.
18. Heiati, H., Tawashi, R., and Phillips, N. C. 1998. Solid lipid nanoparticles as drug carriers II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′- deoxythymidine palmitate in mice. Int. J. Pharm. 174(1-2):71-80.
19. Heiati, H., Tawashi, R., Shivers, R. R., and Phillips, N. C. 1997. Solid lipid nanoparticles as drug carriers 1. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate. Int. J. Pharm. 146:123-131.
20. Highleyman, L. HIV Drugs and the HIV Lifecycle 2003. [Cited 24/10/07] Available from: http://www.thewellproject.org/en_US/ Treatmentand_Trials/Anti_HIV_Meds/Lifecycle_and_ ARVs.jsp.
21. Kawaguchi, T., Hasegawa, T., Juni, K., and Seki, T. 1991. Rectal absorption of Zidovudine. Int. J. Pharm. 77(1):71-74.
22. Kawaguchi, T., Hasegawa, T., Seki, T., Juni, K., Morimoto, Y., Miyakawa, A., and Saneyoshi, M. 1992. Prodrugs of 2′,3′-dideoxyinosine (DDI): improved oral bioavailability via hydrophobic esters. Chem. Pharm. Bull (Tokyo) 40(5):1338-1340.
23. Kuo, Y. C., and Kuo, C. Y. 2007. Loading efficiency of stavudine on polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate copolymer nanoparticles. Int. J. Pharm. 351(1-2):271-281.
24. Kuo, Y. C., and Chen, H. H. 2006. Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier. Int. J. Pharm. 327(1-2):160-169.
25. Kuo, Y. C., and Kuo, C. Y. 2007. Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers. Int. J. Pharm.
26. Kuo, Y. C., and Su, F. L. 2007. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmetheorylate, and solid lipid nanoparticles. Int. J. Pharm. 340(1-2):143-152.
27. Lanao, J. M., Briones, E., and Colino, C. I. 2007. Recent advances in delivery systems for anti-HIV1 therapy. J. Drug. Target. 15(1):21-36.
28. Leroux, J. C., Cozens, R., Roesel, J. L., Galli, B., Kubel, F., Doelker, E., and Gurny, R. 1995. Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice. J. Pharm. Sci. 84(12):1387-1391.
29. Löbenberg, R., Araujo, L., and Kreuter, J. 1997. Body distribution of azidothymidine bound to nanoparticles after oral administration. Eur. J. Pharm. Biopharm. 44(2):127-132.
30. Löbenberg, R., Araujo, L., von Briesen, H., Rodgers, E., and Kreuter, J. 1998. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control Release 50(1-3):21-30.
31. Lucas, S. 2001. Update on the pathology of AIDS. Intensive. Crit. Care Nurs. 17(3):155-166.
32. Mamalis, A. G. 2006. Recent advances in nanotechnology. J. Mat. Protec. 181(1-3):52-58.
33. Mirchandani, H., and Chien, Y. W. 1993. Drug delivery approaches for anti-HIV drugs. Int. J. Pharm. 95(1-3):1-21.
34. Naidoo, P. Barriers to HIV care and treatment by doctors: a review of the literature. SA Fam. Pract. 48. (In press).
35. Narishetty, S. T., and Panchagnula, R. 2005. Effect of L-menthol and 1,8-cineole on phase behavior and molecular organization of SC lipids and skin permeation of zidovudine. J. Control Release 102(1):59-70.
36. Pang, S., Koyanagi, Y., Miles, S., Wiley, C., Vinters, H. V., and Chen, I. S. 1990. High levels of unintegrated HIV-1 DNA in brain tissue of AIDS dementia patients. Nature 343(6253):85-89.
37. Pamyam, J., and Labhasetwar, V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3):329-347.
38. Park, K. 2007. Nanotechnology: what it can do for drug delivery. J. Control Release 120(1-2):1-3.
39. Pieribone, D. The HIV Life Cycle 2002/2003. [Cited 24/20/07]. Available from: http://www.thebody.com/content/art 14193.html.
40. Rathbun, R. C., Lockhart, S. M., and Stephens, J. R. 2006. Current HIV treatment guidelines - an overview. Curr. Pharm. Des. 12(9):1045-1063.
41. Sachez-Lafuente, C., Teresa Faucci, M., Fernandez-Arevalo, M., Alvarez-Fuentes, J., Rabasco, A. M., and Mura, P. 2002. Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers. Int. J. Pharm. 234(1-2):213-221.
42. Schafer, V., von Briesen, H., Andreesen, R., Steffan, A. M., Royer, C., Troster, S., Kreuter, J., and Rubsamen-Waigmann, H. 1992. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9(4):541-546.
43. Seki, T., Sato, N., Hasegawa, T., Kawaguchi, T., and Juni, K. 1994. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol. Pharm. Bull. 17(8):1135-1137.
44. Shah, L. K., and Amiji, M. M. 2006. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS. Pharm. Res. 23(11):2638-2645.
45. Shahiwala, A., and Amiji, M. M. 2007. Nanotechnology-based delivery systems in HIV/AIDS therapy. Future HIV Ther. 1(1):49-59.
46. Stoddart, C. A., and Reyes, R. A. 2006. Models of HIV-1 disease: a review of current status. Drug Discov. Today: Dis. Models 3:113-119.
47. Stolnik, S., Illum, L., and Davis, S. S. 1995. Long circulating microparticulate drug carriers. Adv. Drug. Deliv. Rev. 16(2-3):195-214.
48. Torchilin, V. P. 2006. Multifunctional nanocarriers. Adv. Drug. Deliv. Rev. 58(14):1532-1555.
49. UNAIDS: AIDS epidemic update, 2007. 2007. [cited 29/11/07]. Available from: http://www.unaids.org/en/HIV data/2007EpiUpdate/default.asp.
50. Van Eerdenbrugh, B., Froyen, L., Martens, J. A., Blaton, N., Augustijns, P., Brewster, M., and Van den Mooter, G. 2007. Characterization of physicochemical properties and pharmaceutical performance of sucrose co-freeze-dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. Int. J. Pharm. 338(1-2):198-206.
51. Vauthier, C., Dubernet, C., Chauvierre, C., Brigger, I., and Couvreur, P. 2003. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J. Control Release 93(2):151-160.
52. Vyas, S. P., Subhedar, R., and Jain, S. 2006. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J. Pharm. Pharmacol 58(3):321-326.
53. Vyas, T. K., Shah, L., and Amiji, M. M. 2006. Nanoparticulate drug carriers for delivery of HIV/AIDS therapy to viral reservoir sites. Expert Opin Drug Deliv. 3(5):613-628.
54. Wong, H. L., Bendayan, R., Rauth, A. M., Li, Y., and Wu, X. Y. 2007. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug. Deliv. rev. 59(6):491-504.
55. Xiang, J., Fang, X. and Li, X. 2002. Transbuccal delivery of 2′,3′-dideoxycytidine: in vitro permeation study and histological investigation. Int. J. Pharm. 231(1):57-66.
56. Yajima, T., Juni, K., Saneyoshi, M., Hasegawa, T., and Kawaguchi, T. 1998. Direct transport of 2′,3′-didehydro-3′-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats. Biol. Pharm. Bull. 21(3):272-277.